ClinicalTrials.gg

Program

Bevacizumab

Also written as “bevacizumab”, “bevacizumab [Avastin]” and “Avastin (bevacizumab)”.

Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Ovarian Neoplasms · Carcinoma, Hepatocellular, led by 35 companies.

Furthest: phase 4, since Jun 20, 2005185 company-led studies, 20 open or runningNext primary completion: Nov 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche1217 open or runningphase 4since Jun 20, 2005Oct 16, 2002Nov 30, 2026phase 3 · NCT03148418
Fresenius Kabi60 open or runningphase 3since Sep 19, 2017Feb 14, 2014none ahead
AstraZeneca54 open or runningphase 3since Nov 28, 2018Nov 28, 2018none ahead
Outlook Therapeutics51 open or runningphase 3since Feb 6, 2019Feb 6, 2019Dec 2027phase 3 · NCT05112861
Pfizer50 open or runningphase 3since Jan 12, 2005Jan 12, 2005none ahead
Otsuka40 open or runningphase 3since Jan 29, 2021Dec 5, 2007none ahead
Biocad30 open or runningphase 3since Dec 27, 2012Dec 27, 2012none ahead
Innovent Biologics30 open or runningphase 3since Oct 23, 2016Oct 23, 2016none ahead
ago-research-gmbh20 open or runningphase 3since Apr 16, 2013Apr 16, 2013none ahead
GlaxoSmithKline21 open or runningphase 2since Oct 10, 2017Oct 10, 2017Jun 21, 2027phase 2 · NCT06796907
navifus-corporation20 open or runningphase 2since Mar 19, 2024Jun 16, 2020none ahead
oncolytics-biotech21 open or runningphase 2since Feb 25, 2026Jan 7, 2011Aug 30, 2027phase 2 · NCT07446322
ppd-development-lp22 open or runningphase 2since Nov 20, 2024Nov 20, 2024Jul 2028phase 2 · NCT06703073
Sinopharm20 open or runningphase 3since Mar 22, 2022Oct 21, 2019none ahead
aryogen-pharmed-co10 open or runningphase 3since Sep 18, 2017Sep 18, 2017none ahead
Bio-Thera Solutions11 open or runningphase 3since Sep 21, 2023Sep 21, 2023none ahead
bradmer-pharmaceuticals-inc10 open or runningphase 2since May 19, 2009May 19, 2009none ahead
centus-biotherapeutics-limited10 open or runningphase 3since Jun 3, 2016Jun 3, 2016none ahead
Corcept Therapeutics11 open or runningphase 2since Apr 1, 2025Apr 1, 2025Dec 2027phase 2 · NCT06906341
geron-corporation10 open or runningphase 2since Dec 2, 2010Dec 2, 2010none ahead
gradalis-inc10 open or runningphase 2since Mar 1, 2012Mar 1, 2012none ahead
iOMEDICO10 open or runningphase 4since Aug 28, 2014Aug 28, 2014none ahead
Jeil Pharmaceutical11 open or runningphase 2since Jan 12, 2026Jan 12, 2026Dec 31, 2029phase 2 · NCT07370818
Johnson & Johnson10 open or runningphase 2since Jun 12, 2008Jun 12, 2008none ahead
laboratorio-elea-phoenix-s-a10 open or runningphase 3since Sep 4, 2018Sep 4, 2018none ahead
Laboratorios Sophia S.A de C.V.10 open or runningphase 3since Jan 19, 2022Jan 19, 2022none ahead
laboratorios-richmond-s-a-c-i-f10 open or runningphase 1since Apr 15, 2019Apr 15, 2019none ahead
mabscale-llc11 open or runningphase 3since Dec 8, 2022Dec 8, 2022Dec 2026phase 3 · NCT05654454
Merck10 open or runningphase 3since Jul 1, 2020Jul 1, 2020none ahead
pharmatech10 open or runningphase 2since Oct 1, 2008Oct 1, 2008none ahead
prologue-research-international10 open or runningphase 3since Jun 5, 2003Jun 5, 2003none ahead
Sino Biopharmaceutical10 open or runningphase 1since Jul 18, 2022Jul 18, 2022none ahead
sirtex-medical10 open or runningphase 3since Aug 13, 2008Aug 13, 2008none ahead
the-emmes-company-llc10 open or runningphase 3since Oct 22, 2013Oct 22, 2013none ahead
xoft-inc10 open or runningphase 2since Dec 17, 2020Dec 17, 2020none ahead

Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, Gilead Sciences, adagene-inc, tempest-therapeutics, nikang-therapeutics-inc, immune-onc-therapeutics, inflarx-gmbh, edesa-biotech-inc, icad-inc, quintiles-inc, fp-clinical-pharma-s-r-l, syngene, wuxi-cds-clinical-research-shanghai-co-ltd, libbs-farmace-utica-ltda and Sanofi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since May 9, 2017.

  1. Mar 22, 2022Phase 3 study in Non-squamous Non-small-cell Lung CancerSinopharm · NCT05318443 · 512 enrolled · China
  2. Jul 18, 2022Sino Biopharmaceutical's first study: phase 1 study in Rectal NeoplasmsNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05476341 · 98 enrolled · China
  3. Dec 8, 2022mabscale-llc's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to mabscale-llcmabscale-llc · NCT05654454 · 620 planned · Russian Federation
  4. Mar 2, 2023Phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT05775159 · 294 enrolled · United States, China, Hong Kong and more
  5. Sep 11, 2023Phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT06040099 · 58 enrolled · United States
  6. Sep 21, 2023Bio-Thera Solutions's first study: phase 3 study in Uterine Cervical NeoplasmsNew to Bio-Thera SolutionsBio-Thera Solutions · NCT06123884 · 526 planned · China
  7. Dec 19, 2023Phase 3 study in Macular DegenerationOutlook Therapeutics · NCT06190093 · 400 enrolled · United States
  8. Mar 19, 2024Phase 2 study in Glioblastomanavifus-corporation · NCT06329570 · 10 enrolled · United States
  9. Nov 20, 2024ppd-development-lp's first studies: 2 phase 2 studies in Respiratory Distress SyndromeNew to ppd-development-lpppd-development-lp · NCT06703073, NCT06701656
  10. Jan 22, 2025Phase 2 study in NeoplasmsGlaxoSmithKline · NCT06796907 · 305 planned · United States, Argentina, Australia and more
  11. Apr 1, 2025Corcept Therapeutics's first study: phase 2 study in Ovarian NeoplasmsNew to Corcept TherapeuticsCorcept Therapeutics · NCT06906341 · 270 planned · United States, Belgium, France and more
  12. Jan 12, 2026Jeil Pharmaceutical's first study: phase 2 study in Ovarian NeoplasmsNew to Jeil PharmaceuticalJeil Pharmaceutical · NCT07370818 · 81 planned · South Korea
  13. Feb 25, 2026Phase 2 study in Ras-mutated Metastatic Colorectal CancerPhase 2 reachedoncolytics-biotech · NCT07446322 · 60 planned · United States
  14. Nov 16, 2026Primary completion moved from 2026-08 to 2027-12Date moved laterphase 2 · +16 months · NCT06906341

Ahead

  1. Nov 30, 2026Primary completion: phase 3 study in NeoplasmsHoffmann-La Roche · NCT03148418
  2. Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell Lungmabscale-llc · NCT05654454
  3. Jun 21, 2027Primary completion: phase 2 study in NeoplasmsGlaxoSmithKline · NCT06796907
  4. Jun 30, 2027Primary completion: phase 3 study in NeoplasmsHoffmann-La Roche · NCT05112965

TargetBeta

VEGFA →read by rule
“A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine”NCIt, by rule
“Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule

Other programs on VEGFA

ProgramCompanyFurthest phaseStudies
RanibizumabruleNovartisphase 4108
afliberceptruleRegeneron Pharmaceuticalsphase 489
faricimabruleHoffmann-La Rochephase 417
ivonescimabruleAkesophase 348
pumitamigBioNTechphase 334
tivunatamigPfizerphase 315
suvemcitugruleSimcere Pharmaceutical Groupphase 36
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
surabgene lomparvovecAbbViephase 32
ABBV-1480RemeGenphase 32
HLX37Fosun Pharmaphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24

Studies

The newest 60 of 185 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07446322Ras-mutated Metastatic Colorectal Cancer · United States2Recruitingoncolytics-biotechAug 30, 202760
NCT07370818Ovarian Neoplasms · South Korea2Not yet recruitingJeil PharmaceuticalDec 31, 202981
NCT06906341Ovarian Neoplasms · United States, Belgium, France and more2RecruitingCorcept TherapeuticsDec 2027270
NCT06796907Neoplasms · United States, Argentina, Australia and more2RecruitingGlaxoSmithKlineJun 21, 2027305
NCT06703073Respiratory Distress Syndrome · United States2Recruitingppd-development-lpJul 2028600
NCT06701656Respiratory Distress Syndrome · United States2Recruitingppd-development-lpJul 2028200
NCT06329570Glioblastoma · United States2Suspendednavifus-corporationDec 31, 202710
NCT06190093Macular Degeneration · United States3CompletedOutlook TherapeuticsNov 7, 2024400
NCT06123884Uterine Cervical Neoplasms · China3RecruitingBio-Thera SolutionsSep 2026526
NCT06040099Carcinoma, Hepatocellular · United States2Active, not recruitingAstraZenecaJun 30, 202658
NCT05775159Carcinoma, Hepatocellular · United States, China, Hong Kong and more2Active, not recruitingAstraZenecaOct 27, 2026294
NCT05654454Carcinoma, Non-Small-Cell Lung · Russian Federation3Recruitingmabscale-llcDec 2026620
NCT05476341Rectal Neoplasms · China1CompletedSino BiopharmaceuticalAug 18, 201798
NCT05318443Non-squamous Non-small-cell Lung Cancer · China3CompletedSinopharmDec 26, 2022512
NCT05217680Diabetic Macular Edema · Mexico3CompletedLaboratorios Sophia S.A de C.V.Aug 18, 2025509
NCT05112965Neoplasms · China3Active, not recruitingHoffmann-La RocheJun 30, 202749
NCT05112861Macular Degeneration · United States3Active, not recruitingOutlook TherapeuticsDec 2027120
NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more1RecruitingHoffmann-La RocheAug 31, 2030542
NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more2Active, not recruitingHoffmann-La RocheFeb 28, 2028176
NCT04737187Colorectal Neoplasms · United States, Austria, Belgium and more3CompletedOtsukaJul 19, 2022492
NCT04732286Carcinoma, Hepatocellular · Spain3TerminatedHoffmann-La RocheApr 26, 2024100
NCT04681677Glioblastoma · United States2Terminatedxoft-incApr 24, 202412
NCT04677504Biliary Tract Neoplasms · United States, China, Hong Kong and more2CompletedHoffmann-La RocheMay 16, 2022162
NCT04524871Advanced Liver Cancers · United States, China, France and more2Active, not recruitingHoffmann-La RocheJul 30, 2027518
NCT04516278Macular Degeneration · United States3CompletedOutlook TherapeuticsFeb 10, 2021197
NCT04487067Carcinoma, Hepatocellular · Italy3CompletedHoffmann-La RocheAug 13, 2024152
NCT04456699Colorectal Neoplasms · United States, Australia, Belgium and more3CompletedMerckMar 27, 2023335
NCT04446416Glioblastoma · Taiwan–Completednavifus-corporationSep 30, 20226
NCT04426825Carcinoma, Non-Small-Cell Lung · China2CompletedHoffmann-La RocheJan 19, 202223
NCT04408989Healthy Volunteers · New Zealand1CompletedFresenius KabiAug 20, 2021114
NCT04238663Healthy Volunteers · Germany1CompletedFresenius KabiMar 17, 2020115
NCT04238650Healthy Volunteers · Japan1CompletedFresenius KabiDec 27, 201949
NCT04135898Healthy Male · China1CompletedSinopharmMar 16, 202088
NCT04325698Advanced Non-squamous NSCLC · China3TerminatedPfizerMay 10, 20218
NCT04126044Pharmacokinetics · China1WithdrawnPfizerJul 10, 20210
NCT04102098Carcinoma, Hepatocellular · United States, Australia, Austria and more3CompletedHoffmann-La RocheOct 21, 2022668
NCT04091217Melanoma · China2CompletedHoffmann-La RocheAug 31, 202243
NCT04068610Colonic Neoplasms · United States, Australia, Canada and more2Active, not recruitingAstraZenecaOct 10, 202261
NCT03919448Pharmacokinetics · Argentina1Completedlaboratorios-richmond-s-a-c-i-fSep 11, 2019112
NCT03847428Carcinoma, Hepatocellular · United States, Australia, Austria and more3CompletedAstraZenecaMay 15, 2026908
NCT03844074Macular Degeneration · Australia3CompletedOutlook TherapeuticsJul 23, 202061
NCT03834753Macular Degeneration · United States3CompletedOutlook TherapeuticsJun 7, 2021228
NCT03794440Carcinoma, Hepatocellular · China3UNKNOWNInnovent BiologicsDec 2022595
NCT03778957Carcinoma, Hepatocellular · United States, Australia, Brazil and more3Active, not recruitingAstraZenecaSep 11, 2023724
NCT03690739Ovarian Neoplasms · Germany3Terminatedago-research-gmbhMar 3, 20219
NCT03693573Carcinoma, Renal Cell3WithdrawnHoffmann-La RocheAug 14, 20210
NCT03668054Macular Degeneration · Argentina3Completedlaboratorio-elea-phoenix-s-aMay 30, 201822
NCT03635489Ovarian Neoplasms · China3CompletedHoffmann-La RocheMay 26, 2021100
NCT03555149Colorectal Neoplasms · United States, Australia, France and more2TerminatedHoffmann-La RocheSep 26, 202296
NCT03434379Carcinoma, Hepatocellular · United States, Australia, Canada and more3CompletedHoffmann-La RocheAug 31, 2020558
NCT03424005Breast Neoplasms · United States, Australia, France and more2RecruitingHoffmann-La RocheSep 30, 20301,132
NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2TerminatedHoffmann-La RocheOct 14, 2025314
NCT03326193Ovarian Neoplasms · United States2CompletedGlaxoSmithKlineDec 24, 2020105
NCT03296163Carcinoma, Non-Small-Cell Lung · Brazil, Bulgaria, Chile and more3CompletedFresenius KabiJul 3, 2019627
NCT03288987Colorectal Neoplasms · Iran, Islamic Republic of3Completedaryogen-pharmed-coJul 30, 2018126
NCT03293654Healthy Volunteers · United Kingdom1CompletedFresenius KabiMay 29, 2019114
NCT03280563Breast Neoplasms · United States, Israel, South Korea2CompletedHoffmann-La RocheSep 26, 2024144
NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more2CompletedHoffmann-La RocheFeb 27, 2025341
NCT03178552Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingHoffmann-La RocheJun 30, 20271,000
NCT03148418Neoplasms · United States, Argentina, Australia and more3Active, not recruitingHoffmann-La RocheNov 30, 2026382

How it is read

Names in the registry

  • “Bevacizumab”, 133 entries
  • “bevacizumab”, 31 entries
  • “bevacizumab [Avastin]”, 20 entries
  • “Avastin (bevacizumab)”, 6 entries
  • “Utidelone combined with Bevacizumab”, 3 entries

Codes read as this program: MB02.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.